Natera, Inc.
This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care. The primary objective is to evaluate the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 microdeletion (DiGeorge syndrome) in this large cohort of pregnant women. This will be done by performing a review of perinatal medical records and obtaining biospecimens after birth to perform genetic diagnostic testing for 22q11.2 deletion. Results from the follow-up specimens will be compared to those obtained by the Panorama screening test to determine test performance. Specific test performance parameters will include: PPV, specificity, and sensitivity.
22q11 Deletion Syndrome
DiGeorge Syndrome
Trisomy 21
Trisomy 18
Trisomy 13
Monosomy X
Sex Chromosome Abnormalities
Cri-du-Chat Syndrome
Angelman Subscription
Prader-Willi Syndrome
1p36 Deletion Syndrome
The primary objective is to determine in a prospective study the performance of SNP based NIPT for the 22q11.2 microdeletion (DiGeorge syndrome) in a large cohort of pregnant women clinically opting for this form of screening. Specific test performance parameters will include: positive predictive value (PPV), specificity, and sensitivity. Secondary objectives include: 1. Determine the test performance (PPV, specificity) of SNP based NIPT for detecting other microdeletion syndromes available in the Panorama microdeletion panel (e.g., 1p36 deletion, Cri-du-chat, Prader-Willi, and Angelman) individually and all combined (including 22q11.2). Given the incidences of \<1:5000, the confidence intervals are expected to be large. 2. Determine the failure ('no call') rate for the Next-generation Aneuploidy Test Using SNPs (NATUS) method for 22q11.2 detection, as well as for aneuploidy. 3. Determine whether a more precise risk for aneuploidy can be generated in the setting of low fetal fraction by incorporating maternal BMI (adjusted fetal fraction percentile). 4. Assess whether low fetal fraction is associated with specific ultrasound findings that may indicate aneuploidy (e.g. triploidy, trisomy 13 and 18). 5. Investigate the relationship between NIPT and sonographic (nuchal translucency and anatomy survey) markers and serum markers from 1st and 2nd trimester aneuploidy screening. 6. Determine sensitivity, specificity, and PPV for chromosomal aneuploidies and sex chromosome abnormalities. 7. Perform detailed assessment of false positive aneuploidy samples to better understand sources of error, including placental studies to further refine issues surrounding mosaicism as NIPT represents circulating placental DNA. 8. Investigate any relationships between circulating placental DNA (fetal fraction) or other test parameters including potential genotypic markers, and outcomes related to abnormal placentation (including but not limited to preeclampsia, small for gestational age and morbidly adherent placenta). 9. Investigate other risk factors that may impact risk assessment for microdeletions including sonographic findings consistent with 22q11.2 (cardiac anomalies and thymus size).
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 20960 participants |
Official Title : | SNP-based Microdeletion and Aneuploidy RegisTry |
Actual Study Start Date : | 2015-04 |
Estimated Primary Completion Date : | 2020-06 |
Estimated Study Completion Date : | 2020-06 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 48 Years |
Sexes Eligible for Study: | FEMALE |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University of California, San Francisco
San Francisco, California, United States, 94158
Not yet recruiting
Cooper University Hospital
Camden, New Jersey, United States, 08103
Not yet recruiting
Virtua
Mount Laurel, New Jersey, United States, 08054
Not yet recruiting
St. Peter's University
New Brunswick, New Jersey, United States, 08901
Not yet recruiting
Complete Women's Healthcare
Garden City, New York, United States, 11530
Not yet recruiting
North Shore University Hospital
Manhasset, New York, United States, 11030
Not yet recruiting
Madonna Perinatal
Mineola, New York, United States, 11501
Not yet recruiting
Long Island Jewish Medical Center
New Hyde Park, New York, United States, 11040
Not yet recruiting
New York University
New York, New York, United States, 10016
Not yet recruiting
Icahn School of Medicine Mt Sinai
New York, New York, United States, 10029
Not yet recruiting
Columbia University
New York, New York, United States, 10032
Not yet recruiting
Montefiore Medical Center
New York, New York, United States, 10461
Not yet recruiting
Suffolk OB
Port Jefferson, New York, United States, 11777
Not yet recruiting
North Austin Maternal Fetal Medicine
Austin, Texas, United States, 78758
Not yet recruiting
Zeid Women's Health Center
Longview, Texas, United States, 75601
Not yet recruiting
University of Utah
Salt Lake City, Utah, United States, 84132
Not yet recruiting
Royal Prince Alfred
Camperdown, New South Wales, Australia, 2050
Not yet recruiting
Royal College Surgeons in Ireland
Dublin, Ireland, 1
Not yet recruiting
left
Barcelona, Spain, 08028
Not yet recruiting
Sahlgrenska University Hospital
Gothenburg, Sweden, SE-416 85
Not yet recruiting
St. George University Hospital
London, United Kingdom, SW17 0QT